>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

APPS +21.8%, CUTR +18.2%, ESPR +15.5%, ITI +14.2%, TWLO +13.8%,KORS +13.6%, MDCA +12.3%, VERI +12.3%, ETRM +11.7%, TCMD+11.2%, MTNB +9.6%, CTSO +9.5%, VRX +9.5%, EGLE +8.9%, MTW+8.6%, LC +8.1%, GTN +8.1%, LMNX +7.7%, RPD +7.6%, TPC +7.1%, IPHI+7%, APPF +6.4%, DNR +6.1%, QTNA +5.8%, ENDP +5.8%, KITE +5.7%,VRAY +5.1%, RL +4.9%, KURA +4.8%, TCCO +4.8%, GAIA +4.7%, DPLO+4.7%, BKD +4.2%, MXWL +3.9%, VYGR +3.8%, GILT +3.7%, LQ +3.6%,CDEV +3.5%, TWOU +3.1%, PRAH +3.1%, LNG +3.1%, USCR +2.8%, CHFS+2.8%, SEE +2.6%, LGND +2.5%, TRHC +2.5%, ARMK +2.4%, NEOS+2.2%, IEP +2.2%, ACM +2.1%, KOPN +2.1%, TDG +2%, WHF +2%, PEGI+1.9%, NCLH +1.8%, EVHC +1.7%, AGII +1.4%, KPTI +1.4%, SNHY +1%,BLD +1%, VRTU +1%

Other news:

FGEN +60.8% (announces positive topline results of its Phase 2 study and two combination sub-studies of pamrevlumab in IPF with earnings)
ESPR +15.5% (reports top-line results from the Phase 2 study evaluating the LDL-C lowering efficacy of the bempedoic acid/ezetimibe combination plus atorvastatin in patients with hypercholesterolemia met primary endpoint)
VG +7% (will replace CoreSite Realty in the S&P SmallCap 600)
ENDP +5.8% (reaches agreement to resolve virtually all known U.S. mesh product liability claims and that it is engaged in discussions to resolve the known remaining U.S. claims at reasonable values )
INOV +2.8% (began receiving Medicare FFS data under the Centers for Medicare & Medicaid Services Qualified Entity Program for all 50 states during 2Q)
XXII +1.2% (continued momentum)

Analyst comments: